Moderna D
D
MRNA
247.000
USD
-5.07
(-2.02%)
Pre Open·252.480USD+5.480(+2.22%)
Last updated: · Delayed 15 min
Moderna stock forecast 2026–2028What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Moderna is 140.20, 43.2% below the current price of 247.00. Their targets range from 25.00 to 305.00.
Of the 16 firms that rated Moderna in the past 12 months, 2 rate it buy or strong buy, 9 hold and 5 sell or strong sell (each firm at its latest rating): a Hold consensus.
12-month price target
140.20 USD
-43.24%
Analysts' 1-year price targets range from 25.00 to 305.00, with an average of 140.20.
Past year
1-year forecast
Strong sellStrong buy
Hold
16 ratings
| Buy | 2 | |
| Hold | 9 | |
| Sell | 5 |
12-month price target
| Highest target | 305.00 |
| Average target | 140.20 |
| Lowest target | 25.00 |
| Current price | 247.00 |
Moderna price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Moderna price target and rating?
See how analysts moved their price target
How analysts rate Moderna, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
2 of 16 firms rate it buy now, against 2 of 11 in December 2025.
Buy Hold Sell
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Moderna analyst upgrades, downgrades and price targets
The latest rating change came on 27 October 2026, when William Blair downgraded Moderna from Outperform to Market Perform. The most recent new target came from Piper Sandler on 9 November 2026: 305.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 9 Nov 2026 | Piper Sandler Edward Tenthoff | Reiterated · Overweight | 230.00 → 305.00 | +32.6% | 271.14 |
| 27 Oct 2026 | William Blair | Downgraded · Outperform → Market Perform | — | — | — |
| 26 Oct 2026 | Piper Sandler | Reiterated · Overweight | 77.00 → 230.00 | +198.7% | 200.10 |
| 15 Oct 2026 | Goldman Sachs Salveen Richter | Reiterated · Neutral | 120.00 → 137.00 | +14.2% | 226.30 |
| 30 Sept 2026 | Citigroup | Downgraded · Neutral → Sell | — | — | — |
| 3 Sept 2026 | UBS | — | 150.00 → 81.00 | -46.0% | 150.81 |
| 3 Sept 2026 | Rothschild & Co | Downgraded · Neutral → Sell | — | — | — |
| 28 Aug 2026 | Argus Research John Eade | Upgraded · Hold → Buy | 180.00 | — | 142.77 |
| 25 Aug 2026 | Wolfe Research | Upgraded · Underperform → Peer Perform | — | — | — |
| 24 Aug 2026 | Barclays Eliana Merle | Reiterated · Equal Weight | 125.00 | — | 145.13 |
| 20 Aug 2026 | UBS Michael Yee | Reiterated · Neutral | 45.00 → 150.00 | +233.3% | 174.38 |
| 19 Aug 2026 | Goldman Sachs | — | 67.00 → 120.00 | +79.1% | 174.38 |
| 19 Aug 2026 | RBC Capital Luca Issi | — | 45.00 → 130.00 | +188.9% | 151.30 |
| 19 Aug 2026 | Loop Capital Markets Leah Rush Cann | — | 135.00 | — | 139.12 |
| 19 Aug 2026 | D.A. Davidson Michael Baker | — | 245.00 | — | 138.21 |
| 19 Aug 2026 | William Blair | Upgraded · Market Perform → Outperform | — | — | — |
| 21 Jul 2026 | Goldman Sachs | Reiterated · Neutral | 49.00 → 67.00 | +36.7% | 59.49 |
| 20 Jul 2026 | Wolfe Research Alexandria Hammond | — | 17.00 → 25.00 | +47.1% | 61.82 |
| 8 Jul 2026 | Morgan Stanley | Reiterated · Equal Weight | 33.00 → 39.00 | +18.2% | 79.77 |
| 7 Jul 2026 | RBC Capital | Reiterated · Sector Perform | 38.00 → 45.00 | +18.4% | 81.80 |
| 26 Jun 2026 | Piper Sandler | Reiterated · Overweight | 63.00 → 77.00 | +22.2% | 67.66 |
| 4 May 2026 | UBS | Reiterated · Neutral | 36.00 → 45.00 | +25.0% | 47.47 |
| 4 May 2026 | RBC Capital Luca Issi | Reiterated · Sector Perform | 30.00 → 38.00 | +26.7% | 46.87 |
| 1 May 2026 | Goldman Sachs | — | 49.00 | — | 45.37 |
| 1 May 2026 | Morgan Stanley | — | 30.00 → 33.00 | +10.0% | 44.18 |
| 3 Mar 2026 | Jefferies Andrew Tsai | — | 30.00 → 37.00 | +23.3% | 49.83 |
| 17 Feb 2026 | RBC Capital Luca Issi | Reiterated · Sector Perform | 25.00 → 30.00 | +20.0% | 42.54 |
| 17 Feb 2026 | Evercore ISI Cory Kasimov | Reiterated · In Line | 32.00 → 35.00 | +9.4% | 43.19 |
| 17 Feb 2026 | Bernstein | — | 45.00 | — | 42.23 |
| 16 Feb 2026 | UBS | — | 34.00 → 36.00 | +5.9% | 42.23 |
| 16 Feb 2026 | Morgan Stanley | — | 28.00 → 30.00 | +7.1% | 42.23 |
| 6 Jan 2026 | UBS | — | 18.00 → 34.00 | +88.9% | 35.66 |
| 12 Dec 2025 | Morgan Stanley | Reiterated · Equal Weight | 32.00 → 28.00 | -12.5% | 29.90 |
| 12 Dec 2025 | Jefferies | — | 30.00 | — | 29.62 |
| 21 Nov 2025 | RBC Capital Luca Issi | Reiterated · Sector Perform | 25.00 | — | 23.10 |
| 21 Nov 2025 | UBS | — | 40.00 → 18.00 | -55.0% | 22.36 |
| 21 Nov 2025 | Piper Sandler | Reiterated · Overweight | 63.00 | — | 22.36 |
| 20 Nov 2025 | Wolfe Research | — | 17.00 | — | 22.36 |
| 17 Nov 2025 | Berenberg Bank | — | 28.00 | — | 24.77 |
Moderna EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
ReportedEstimate
EPS
ReportedEstimate
Does Moderna beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 47.7% off the result, either way, and their revenue estimate 40.9%, over the last 12 quarters.
- EPS beats
- 24 / 32
- Revenue beats
- 18 / 31
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +47.7%
- Since
- March 2019
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 6 Nov 2026 | -1.10 | 0.38 | +134.5% | 890.25M | 1.31B | +47.5% |
| Q2 FY2026 | 31 Jul 2026 | -2.03 | -1.97 | +3.0% | 102.93M | 145.00M | +40.9% |
| Q1 FY2026 | 1 May 2026 | -4.45 | -3.40 | +23.6% | 236.36M | 389.00M | +64.6% |
| Q4 FY2025 | 13 Feb 2026 | -2.54 | -2.11 | +16.9% | 635.15M | 678.00M | +6.7% |
| Q3 FY2025 | 6 Nov 2025 | -1.87 | -0.51 | +72.7% | 920.86M | 1.02B | +10.3% |
| Q2 FY2025 | 1 Aug 2025 | -2.99 | -2.13 | +28.8% | 893.29M | 142.00M | -84.1% |
| Q1 FY2025 | 1 May 2025 | -2.92 | -2.52 | +13.7% | 116.75M | 107.00M | -8.3% |
| Q4 FY2024 | 14 Feb 2025 | -2.68 | -2.50 | +6.7% | 942.82M | 956.00M | +1.4% |
| Q3 FY2024 | 7 Nov 2024 | -1.91 | 0.03 | +101.6% | 1.25B | 1.86B | +48.4% |
| Q2 FY2024 | 1 Aug 2024 | -3.35 | -3.33 | +0.6% | 128.41M | 241.00M | +87.7% |
| Q1 FY2024 | 2 May 2024 | -3.56 | -3.07 | +13.8% | 93.26M | 167.00M | +79.1% |
| Q4 FY2023 | 22 Feb 2024 | -0.97 | 0.55 | +156.7% | 2.51B | 2.81B | +12.0% |
Moderna stock price 2026–2028: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
There are no price scenarios for Moderna: its P/E has been above 60, or from losses, too often in the last five years to price its earnings at, and similar companies' P/Es put its value too far from its price to stand in. The earnings analysts expect are in the estimates above.
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 153.460 | 297.58169Price 153.46471 | +93.9% | |
| 158.080 | 305.52160Price 158.08396 | +93.3% | |
| 156.430 | 300.15225Price 156.43375 | +91.9% | |
| 37.330 | 71.4258Price 37.33193 | +91.3% | |
| 213.990 | 405.47304Price 213.99507 | +89.5% | |
| 125.160 | 236.84178Price 125.16296 | +89.2% | |
| 204.950 | 384.66163Price 204.952,644 | +87.7% |
Furthest below the fair value on each stock's page, updated every day.